CA3253847A1 - HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE - Google Patents
HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USEInfo
- Publication number
- CA3253847A1 CA3253847A1 CA3253847A CA3253847A CA3253847A1 CA 3253847 A1 CA3253847 A1 CA 3253847A1 CA 3253847 A CA3253847 A CA 3253847A CA 3253847 A CA3253847 A CA 3253847A CA 3253847 A1 CA3253847 A1 CA 3253847A1
- Authority
- CA
- Canada
- Prior art keywords
- heterocyclyl
- alkyl
- group
- cycloalkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210330007 | 2022-03-28 | ||
| CN202210330007.4 | 2022-03-28 | ||
| CN202210944231 | 2022-08-05 | ||
| CN202210944231.2 | 2022-08-05 | ||
| CN202211255163.5 | 2022-10-13 | ||
| CN202211255163 | 2022-10-13 | ||
| PCT/CN2023/084265 WO2023185793A1 (zh) | 2022-03-28 | 2023-03-28 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3253847A1 true CA3253847A1 (en) | 2025-07-04 |
Family
ID=88199144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3253847A Pending CA3253847A1 (en) | 2022-03-28 | 2023-03-28 | HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250206760A1 (https=) |
| EP (1) | EP4501925A4 (https=) |
| JP (1) | JP2025509995A (https=) |
| KR (1) | KR20240167844A (https=) |
| CN (1) | CN118715216A (https=) |
| AU (1) | AU2023243776A1 (https=) |
| CA (1) | CA3253847A1 (https=) |
| MX (1) | MX2024011705A (https=) |
| TW (1) | TW202345816A (https=) |
| WO (1) | WO2023185793A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN121969632A (zh) * | 2023-09-27 | 2026-05-01 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的可药用盐、其结晶形式及用途 |
| CN121969633A (zh) * | 2023-09-27 | 2026-05-01 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的结晶形式及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1292591B1 (en) * | 2000-06-22 | 2005-02-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| DK1660090T3 (da) * | 2003-08-14 | 2012-12-17 | Array Biopharma Inc | Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer |
| ATE446294T1 (de) * | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2017148391A1 (zh) | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| TWI858848B (zh) * | 2018-05-08 | 2024-10-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
| EP4523755A3 (en) * | 2018-09-18 | 2025-06-11 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
| EP4100409B1 (en) | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| JP7626774B2 (ja) | 2020-02-03 | 2025-02-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| WO2021179274A1 (en) * | 2020-03-13 | 2021-09-16 | Suzhou Zanrong Pharma Ltd. | ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| WO2021231400A1 (en) | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors |
| TW202214654A (zh) | 2020-06-10 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合喹唑啉類衍生物、其製備方法及其在醫藥上的應用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| US20240398805A1 (en) * | 2021-02-05 | 2024-12-05 | Accutar Biotechnology Inc. | Quinazoline derived compounds as egfr inhibitors and their uses thereof |
| WO2023154124A1 (en) * | 2022-02-09 | 2023-08-17 | Enliven Therapeutics, Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
-
2023
- 2023-03-28 CN CN202380022951.6A patent/CN118715216A/zh active Pending
- 2023-03-28 AU AU2023243776A patent/AU2023243776A1/en active Pending
- 2023-03-28 US US18/851,679 patent/US20250206760A1/en active Pending
- 2023-03-28 JP JP2024556197A patent/JP2025509995A/ja active Pending
- 2023-03-28 KR KR1020247034812A patent/KR20240167844A/ko active Pending
- 2023-03-28 EP EP23778158.8A patent/EP4501925A4/en active Pending
- 2023-03-28 WO PCT/CN2023/084265 patent/WO2023185793A1/zh not_active Ceased
- 2023-03-28 CA CA3253847A patent/CA3253847A1/en active Pending
- 2023-03-28 TW TW112111777A patent/TW202345816A/zh unknown
-
2024
- 2024-09-24 MX MX2024011705A patent/MX2024011705A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023243776A1 (en) | 2024-09-12 |
| US20250206760A1 (en) | 2025-06-26 |
| JP2025509995A (ja) | 2025-04-11 |
| CN118715216A (zh) | 2024-09-27 |
| EP4501925A4 (en) | 2025-08-27 |
| KR20240167844A (ko) | 2024-11-28 |
| EP4501925A1 (en) | 2025-02-05 |
| MX2024011705A (es) | 2024-11-08 |
| WO2023185793A1 (zh) | 2023-10-05 |
| TW202345816A (zh) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7502365B2 (ja) | Ｒｅｔキナーゼ阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 | |
| CA3253847A1 (en) | HETEROCYCLIC COMPOUND CONTAINING NITROGEN, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE | |
| EP3564232B1 (en) | Bmp-signal-inhibiting compound | |
| KR100548853B1 (ko) | 아졸로 트리아진 및 피리미딘 | |
| EP2143724B1 (en) | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | |
| KR20150108389A (ko) | 치환된 피롤로피리미딘 화합물, 이의 조성물 및 이에 의한 치료 방법 | |
| JP2021516242A (ja) | 置換１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン | |
| KR101664460B1 (ko) | 디하이드로피리다진-3,5-디온 유도체 | |
| CA2838784A1 (en) | Pyrazolo[3,4-c]pyridine compounds and methods of use | |
| EP3556761B1 (en) | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | |
| MX2014008201A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso. | |
| EP2945623A1 (en) | Hedgehog pathway signaling inhibitors and therapeutic applications thereof | |
| WO2023192416A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| EA032643B1 (ru) | Имидазопиридазиновые соединения в качестве ингибиторов pik | |
| US20020147338A1 (en) | Pyrazolotriazines as CRF antagonists | |
| KR20170047388A (ko) | 나트륨 의존성 인산 트랜스포터 저해제를 함유하는 의약 | |
| JP2022532145A (ja) | 置換ベンズイミダゾロン化合物 | |
| US20200055852A1 (en) | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | |
| WO2024211346A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| WO2024086789A2 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| CN119855817B (zh) | 杂环炔基取代的酰胺衍生物、其制备方法及其应用 | |
| CN117903172A (zh) | 取代的含氮杂芳基类化合物、其制备方法及其在医药上的应用 | |
| EP3917929A1 (en) | The monohydrate of rogaratinib hydrochloride and solid states thereof | |
| EA052991B1 (ru) | Азотсодержащее гетероциклическое соединение, способ его получения и его фармацевтическое применение | |
| CN116813646A (zh) | 取代桥环类抑制剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240830 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250122 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250122 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250131 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250228 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250314 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250704 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |